Tadalafil may shift neurodegeneration biomarkers in type 2 diabetes
Conclusión Clave:
This small trial analysis tested daily tadalafil in people with type 2 diabetes. Tadalafil lowered some blood biomarkers related to amyloid metabolism and astroglial activation, but it did not change several other brain-related biomarkers.
Estudio de un Vistazo
Qué se estudió
Tadalafil effects on blood-based neurodegeneration biomarkers in type 2 diabetes.
Participantes
Middle Aged (40-64), Older Adults (65+)
Male, Female
with T2 Diabeteswith Obesity
Intervención
Tadalafil
Resultados
Amyloid beta 40, Amyloid beta 42, Glial fibrillary acidic protein, HbA1c, Amyloid beta 42-to-40 ratio, Phospho-tau217, Neurofilament light protein, Growth differentiation factor 15, Fasting blood sugar (FBS)
Financiamiento
No Patrocinado por la Industria
Guarda este estudio y agrega notas a tu biblioteca de investigación.
Efectos Principales
↓ Plasma amyloid-β 40 and amyloid-β 42 compared with placebo
↓ Plasma GFAP compared with placebo
→ No clear effect on amyloid-β 42/40 ratio, pTau217, NfL, or GDF-15
Resumen de Evidencia
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Tadalafil (Medications) |  Amyloid-β 40 (Clinical Outcomes) | Decrease | Mixed |
Tadalafil (Medications) | Amyloid-β 42 (Clinical Outcomes) | Decrease | Mixed |
Tadalafil (Medications) | Amyloid-β 42/40 ratio (Clinical Outcomes) | Uncertain | Limited |
Tadalafil (Medications) |  Fasting blood sugar (FBS) (Glycemic Control) | No Change | Limited |
Tadalafil (Medications) | Glial fibrillary acidic protein (Clinical Outcomes) | Decrease | Mixed |
Tadalafil (Medications) |  Growth differentiation factor 15 (Metabolic Health) | Uncertain | Limited |
Tadalafil (Medications) | HbA1c (Glycemic Control) | Decrease | Limited |
Tadalafil (Medications) | Neurofilament light protein (Clinical Outcomes) | Uncertain | Limited |
Tadalafil (Medications) | Phosphorylated tau217 (Clinical Outcomes) | Uncertain | Limited |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Tener en Cuenta
- Very small per-protocol sample size of 15 participants. Post-hoc biomarker analysis, not powered for these outcomes. No cognitive performance measurements before and after treatment. Some pTau217 measurements were below quantification limits.
Entre Líneas
- Very small per-protocol sample size of 15 participants. Post-hoc biomarker analysis, not powered for these outcomes. No cognitive performance measurements before and after treatment. Some pTau217 measurements were below quantification limits.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.